

CORRIGENDUM: Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

Arshad, U., *et al.*, *Clin. Pharmacol. Ther.* **108**, 775–790 (2020); <https://doi.org/10.1002/cpt.1909>

In the published version of the above article, the authors noticed a correction related to the data presented for baricitinib. The entry for baricitinib within the spreadsheet used for the analysis was erroneous, and the authors are unaware of any antiviral data for this drug. The data relating to baricitinib throughout the manuscript should therefore be disregarded. The inclusion of this erroneous value does not impact the overall interpretations or conclusions from the paper.

The authors apologize for this error.